Methylglyoxal induces death in human brain neuronal cells (SH-SY5Y), prevented by metformin and dapagliflozin

Keyphrases

• Human Brain 100%
• Metformin 100%
• Methylglyoxal 100%
• SH-SY5Y Cells 100%
• Neuronal Cells 100%
• Dapagliflozin 100%
• Peroxynitrite 27%
• Cell Damage 27%
• Type 1 Diabetes Mellitus (T1DM) 27%
• Vascular Complications 18%
• Copyright 18%
• Antidiabetic Agents 18%
• Protective Effect 9%
• Incubation 9%
• Cell Death 9%
• Beneficial Effects 9%
• Insulin Secretion 9%
• Alzheimer's Disease 9%
• Cytotoxicity 9%
• Cell Injury 9%
• Neuropathy 9%
• Diabetic Patients 9%
• Reactive Oxidant Species 9%
• Neurodegenerative Diseases 9%
• Blood Glucose 9%
• LDH Assay 9%
• MTT Assay 9%
• Treatment Conditions 9%
• Treatment Group 9%
• Chronic Hyperglycemia 9%
• Fluorescence Assay 9%
• Laser Scanning Confocal Microscopy 9%
• Dementia Risk 9%
• Brain Cells 9%
• Neurological Complications 9%
• Condition Control 9%
• Insulin Action 9%
• Metabolic Disorders 9%

Neuroscience

• Metformin 100%
• Dapagliflozin 100%
• Diabetes Mellitus 80%
• Cell Damage 80%
• Oxidizing Agent 20%
• Alzheimer's Disease 20%
• Cell Death 20%
• Hyperglycemia 20%
• Neurodegeneration 20%
• Confocal Laser Scanning Microscopy 20%
• Lactate Dehydrogenase 20%
• Cytotoxicity 20%
• MTT Assay 20%
• Metabolic Disorder 20%
• Neuropathy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Metformin 100%
• Methylglyoxal 100%
• Dapagliflozin 100%
• Diabetes Mellitus 36%
• Peroxynitrite 27%
• Antidiabetic Agent 18%
• Oxidizing Agent 9%
• Lactate Dehydrogenase 9%
• Confocal Microscopy 9%
• Alzheimer's Disease 9%
• Hyperglycemia 9%
• Neuropathy 9%
• Fluorescence Assay 9%
• Nerve Degeneration 9%
• Neurological Complication 9%
• Cytotoxicity 9%
• Metabolic Disorder 9%
• Treatment Group 9%